CARDIFF ONCOLOGY, INC. Debt Securities, Available-for-sale, Amortized Cost, Current
CARDIFF ONCOLOGY, INC. (CRDF) had Debt Securities, Available-for-sale, Amortized Cost, Current of $16.19 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Notes › Debt Securities, Available-for-Sale, Amortized Cost
us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent · last filed 2026-08-11
- 2026-06-30: Debt Securities, Available-for-sale, Amortized Cost, Current $16.19M.
- 2026-03-31: Debt Securities, Available-for-sale, Amortized Cost, Current $23.90M.
- 2025-12-31: Debt Securities, Available-for-sale, Amortized Cost, Current $31.93M.
- 2025-09-30: Debt Securities, Available-for-sale, Amortized Cost, Current $41.69M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost, Current |
|---|---|
| 2026-06-30 | $16.19M 10-Q · filed 2026-08-11 |
| 2026-03-31 | $23.90M 10-Q · filed 2026-05-14 |
| 2025-12-31 | $31.93M 10-Q · filed 2026-08-11 |
| 2025-09-30 | $41.69M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $50.38M 10-Q · filed 2025-07-29 |
| 2025-03-31 | $43.06M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $33.98M 10-K · filed 2026-02-24 |
| 2024-09-30 | $35.75M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $33.22M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $42.82M 10-Q · filed 2024-05-02 |
| 2023-12-31 | $26.29M 10-K · filed 2025-02-27 |
| 2023-09-30 | $37.78M 10-Q · filed 2023-11-02 |
| 2023-06-30 | $41.41M 10-Q · filed 2023-08-09 |
| 2023-03-31 | $50.67M 10-Q · filed 2023-05-04 |
| 2022-12-31 | $84.30M 10-K · filed 2024-02-29 |
| 2022-09-30 | $89.22M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $95.64M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $94.91M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $95.64M 10-K · filed 2023-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B |